Steve has 18 years’ pharmaceutical development experience in AstraZeneca, holding leadership roles in several areas for over a decade, most recently as Director – Chemical Development, Process Chemistry. He has led teams delivering drug projects across all stages of chemical development, from pre-clinical through clinical to launch. Currently, Steve leads a New Modalities Synthesis group, which includes oligonucleotide, peptide and antibody-drug conjugate payload programmes. He is small-molecule SME for late-stage development of ADC payloads, looking at both AZ internal programmes and external collaborations.